What is the recommended management for postmenopausal osteoporosis?

Postmenopausal Osteoporosis Prescription Management

Diagnostic Confirmation

Before initiating treatment, confirm osteoporosis diagnosis with DEXA scan showing T-score ≤ -2.5, or consider treatment for T-score between -1.0 and -2.5 if FRAX shows ≥20% risk of major osteoporotic fracture OR ≥3% risk of hip fracture. 1, 2, 3

• Treatment should also be initiated in patients with a history of low-trauma fracture, even without osteoporotic T-scores on DEXA 1, 3

---

First-Line Pharmacologic Treatment

Initiate bisphosphonate therapy as first-line treatment based on the strongest evidence for fracture reduction and cost-effectiveness. 1, 2, 3

Specific Bisphosphonate Options:

• Alendronate 70 mg orally once weekly (preferred due to robust fracture data and generic availability) 1, 3

  • Take on empty stomach in the morning, 30-60 minutes before first food/drink 1
  • Swallow with full glass of plain water while upright 1
  • Remain upright for at least 30 minutes after administration 1

• Risedronate 35 mg orally once weekly (alternative option) 1, 3, 4

  • Take immediately following breakfast (not fasting) to reduce risk of abdominal pain 4
  • Swallow whole with at least 4 ounces of plain water while upright 4
  • Do not chew, cut, or crush tablets 4
  • Remain upright for 30 minutes after taking 4

• Zoledronic acid 5 mg IV annually (for patients unable to tolerate oral bisphosphonates) 1

Expected Benefits:

• Bisphosphonates reduce vertebral fractures by 47-56% and hip fractures by approximately 50% over 3 years 3, 5
• Alendronate demonstrates greater BMD gains and bone turnover marker reductions compared to risedronate in head-to-head trials 6

---

Essential Supplementation

All patients must receive calcium and vitamin D supplementation concurrently with bisphosphonate therapy. 1, 2, 3

• Calcium 1,200 mg daily 2, 3
• Vitamin D 800 IU daily (target serum level ≥20 ng/mL) 2, 3
• Critical: Administer calcium supplements, antacids, magnesium-based products, and iron preparations at a different time of day than bisphosphonates to avoid interference with absorption 4

---

Mandatory Lifestyle Modifications

Counsel all patients on non-pharmacologic interventions that complement medication therapy. 1, 2, 3

• Weight-bearing exercise (walking, dancing, resistance training) 1, 2, 3
• Smoking cessation 1, 2, 3
• Limit alcohol intake to reduce fall and fracture risk 1, 2, 3
• Fall prevention evaluation and counseling 1

---

Treatment Duration and Monitoring

Prescribe bisphosphonates for an initial 5-year treatment period. 1, 2, 3

• Do NOT monitor bone density during the initial 5-year treatment period 1, 2, 3
• After 5 years, reassess fracture risk to determine if treatment continuation is warranted 1, 2, 3
• Evidence suggests that extending bisphosphonate therapy beyond 5 years may reduce vertebral fractures but increases risk of long-term harms (atypical femoral fractures, osteonecrosis of jaw) 1
• Consider stopping after 5 years unless patient has very high fracture risk or history of fractures on therapy 1

---

Second-Line Treatment Option

If bisphosphonates are contraindicated or not tolerated, prescribe denosumab 60 mg subcutaneously every 6 months. 1, 2

• Denosumab is appropriate for patients with contraindications to bisphosphonates (esophageal abnormalities, inability to remain upright, severe renal impairment) 1
• Critical warning: Never abruptly discontinue denosumab without transitioning to a bisphosphonate due to severe risk of rebound multiple vertebral fractures 2, 3

---

Alternative Agents (Specific Indications Only)

Raloxifene 60 mg daily:

• Consider only in younger postmenopausal women at lower fracture risk 1
• Contraindicated in patients with history of venous thromboembolism 1

Teriparatide 20 mcg subcutaneously daily:

• Reserve for severe osteoporosis with very high fracture risk or patients who have failed bisphosphonate therapy 1
• Must transition to antiresorptive agent (bisphosphonate or denosumab) after completing teriparatide course to preserve gains 1

Calcitonin:

• Use only as last resort in patients who cannot tolerate any other options due to weaker efficacy data 1

---

Critical Safety Monitoring

Counsel patients about potential adverse effects and when to seek medical attention. 1, 3

Bisphosphonate-Related:

• Upper GI symptoms (abdominal pain, nausea, dyspepsia) are usually transient 5
• Rare but serious: osteonecrosis of jaw and atypical femoral fractures (risk increases with duration >5 years) 1, 3
• Contraindicated in patients with esophageal abnormalities or inability to stand/sit upright for 30 minutes 1

Denosumab-Related:

• Mild GI symptoms, increased infection risk, rash/eczema 2, 3
• Rebound fracture risk if discontinued without transition therapy 2, 3

---

Common Pitfalls to Avoid

Ensure proper bisphosphonate administration technique to minimize GI adverse effects and maximize absorption—this is the most common reason for treatment failure 3

Never prescribe bisphosphonates without concurrent calcium and vitamin D supplementation—pharmacologic therapy is significantly less effective without adequate supplementation 3

Do not use oral bisphosphonates in patients with esophageal varices or portal hypertension due to risk of precipitating variceal hemorrhage 1

If patient misses weekly bisphosphonate dose, instruct to take one tablet the morning after remembering, then return to original schedule—never take two tablets on same day 4

Prescribe generic formulations whenever possible rather than brand-name medications for cost-effectiveness 1